PBAC's latest decision on Epoetin lambda: Recommended with restriction (2017). Considered for Anaemia associated with intrinsic renal disease (chronic renal failure) during correction and maintenance therapy phases.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2010
Submissions
2
2010 → 2017
Eligible population
Patients with symptomatic or transfusion-requiring anaemia associated with chronic renal failure.
Therapy area
Haematology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
epoetin alpha (cost-minimisation basis)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as this was a minor submission requesting a restriction change only.
Submission history
Jul 2010: Recommended with restriction · Restricted | Authority Required
Jul 2017: Recommended with restriction · Restricted